We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cognition Therapeutics Inc (CGTX) USD0.001

Sell:$0.74 Buy:$0.74 Change: $0.10 (11.99%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.74
Buy:$0.74
Change: $0.10 (11.99%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.74
Buy:$0.74
Change: $0.10 (11.99%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.

Contact details

Address:
Suite 261, 2403 Sidney Street
PITTSBURGH
15203
United States
Telephone:
+1 (412) 7701621
Website:
https://cogrx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CGTX
ISIN:
US19243B1026
Market cap:
$34.90 million
Shares in issue:
41.55 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Lisa Ricciardi
    President, Chief Executive Officer, Director
  • John Doyle
    Chief Financial Officer
  • Anthony Caggiano
    Chief Medical Officer, Head of R&D

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.